This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

E'

1. (Currently Amended) A multi-phase combination preparation comprising a predetermined ordered daily sequence of at least 28 individual daily dosage units ~~comprising~~ for administration to a patient, wherein the predetermined ordered daily sequence comprises

a first phase of at least 21 initial dosage units to be administered daily to said patient according to said predetermined order, each individual dosage unit comprising a competitive progesterone antagonist in an effective amount to inhibit ovulation during the first phase, ~~and~~ followed in the ordered sequence by

a second phase of 5 to 28 ~~daily~~ separate dosage units to be administered daily to said patient, wherein each dosage unit of ~~this~~ the second phase ~~comprising~~ comprises a gestagen,

wherein the daily dosage units are to be taken daily by a user in the ordered sequence such that the daily units of progesterone antagonist are taken initially followed by separate administration of the daily dosage units of gestagen.

2. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises 21 to 27 initial daily dosage units.

3. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises at least 28 and at most 77 initial daily dosage units.

4. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises 28 initial daily dosage units.

5. (Previously Amended) A multi-phase combination preparation of claim 1, wherein the second phase comprises 7 to 14 daily dosage units.

6. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises 21 initial daily dosage units and a second phase comprises 7 daily dosage units.

7. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises 23 or 24 initial daily dosage units and the second phase comprises 8, 7 or 6 daily dosage units, whereby the total number of daily dosage units of the first and the second phases is 30 or 31.

8. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises 70 initial daily dosage units and the second phase comprises 14 daily dosage units.

E/cont.

9. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises 63 initial daily dosage units and the second phase comprises 7 daily dosage units.

10. (Previously Amended) A multi-phase combination preparation of claim 1, wherein the competitive progesterone antagonist is:

17α-ethinyl-17β-hydroxy-11β-(4-methoxyphenyl)estra-4,9-dien-3-one,

11β-(4-acetylphenyl)-17β-hydroxy-17α-(1-propenyl)estra-4,9-dien-3-one,

(Z)-11β-(4-acetylphenyl)-17β-hydroxy-17α-(3-hydroxy-1-propenyl)estra-4,9-dien-3-one,

11β-(4-dimethylaminophenyl)-17β-hydroxy-17α-(1-propinyl)estra-4,9-dien-3-one,

(Z)-9,11α-dihydro-17β-hydroxy-17α-(3-hydroxy-1-propenyl)-6'-(3-pyridinyl)-4'*H*-naphth[3',2',1': 10,9,11]estra-4,9(11)-dien-3-one,

(Z)-11β-[4-(dimethylamino)phenyl]-17β-hydroxy-17α-(3-hydroxy-1-propenyl)-estr-4-en-3-one,

4',5'-dihydro-11β-[4-(dimethylamino)phenyl]-6β-methylspiro[estra-4,9-dien-17β, 2'(3'*H*)-furan]-3-one,

4',5'-dihydro-11β-[4-(dimethylamino)phenyl]-7β-methylspiro[estra-4,9-dien-17β, 2'(3'*H*)-furan]-3-one, or

11β-(4-acetylphenyl)-19,24-dinor-17,23-epoxy-17α-chola-4,9,20-trien-3-one,

or a mixture thereof.

11. (Previously Amended) A multi-phase combination preparation of claim 1, wherein the gestagen is:

gestodene,
progesterone,
levonorgestrel,
cyproterone acetate,
chlormadinone acetate,
drospirenone (dihydrospirorenone),
norethisterone,
norethisterone acetate,
norgestimate,
desogestrel,
3-ketodesogestrel, or
dienogest,

or a mixture thereof.

E/cont.

12. (Original) A multi-phase combination preparation of claim 1, wherein the daily dosage of the gestagen is:

0.02-0.6 mg of levonorgestrel,
0.02-2.0 mg of cyproterone acetate,
0.01-0.3 mg of gestodene, or
0.02-0.3 mg of desogestrel,

or a bioequivalent dosage of another gestagen.

13. (withdrawn) A multi-phase combination preparation of claim 1, wherein the gestagen gestodene is in a dosage of 0.02 to 0.075 mg.

14. (withdrawn) A multi-phase combination preparation of claim 1, wherein the competitive progesterone antagonist (Z)-11β-[4-(dimethylamino)phenyl]-17β-hydroxy-17α-(3-hydroxy-1-propenyl)estr-4-en-3-one is in a dosage of 0.01-5 mg.

15. (Currently Amended) A contraceptive kit comprising a predetermined ordered daily sequence of at least 28 individual daily dosage units ~~comprising~~ for administration to a patient, wherein the predetermined ordered daily sequence comprises

a first phase of at least 21 initial ~~daily~~ dosage units to be administered daily to said patient according to said predetermined order, each individual dosage unit comprising a competitive progesterone antagonist in an effective amount to inhibit ovulation during the first ~~above-named~~ phase; ~~and~~ followed in the ordered sequence by

a second phase of 5 to 28 separate ~~daily~~ dosage units to be administered daily to said patient, wherein each dosage unit of the second phase ~~comprising~~ comprises a gestagen,

E'coint. wherein the daily dosage units are to be taken daily by a user in the ordered sequence such that the daily units of progesterone antagonist are taken initially followed by separate administration of the daily dosage units of gestagen.

16. (Original) A contraceptive kit of claim 15, wherein the first phase comprises 21 to 27 initial daily dosage units.

17. (Original) A contraceptive kit of claim 15, wherein the first phase comprises at least 28 and at most 77 initial daily dosage units.

18. (Original) A contraceptive kit of claim 15, wherein the first phase comprises 28 initial daily dosage units.

19. (Original) A contraceptive kit of claim 15, wherein the second phase comprises 10 to 25 daily dosage units.

20. (Original) A contraceptive kit of claim 15, wherein the first phase comprises 21 initial daily dosage units and the second phase comprises 7 daily dosage units.

21. (Original) A contraceptive kit of claim 15, wherein the first phase comprises 23 or 24 initial daily dosage units and the second phase comprises 8, 7 or 6 daily dosage units, whereby the total number of daily dosage units of the first and the second phases is 30 or 31.

22. (Original) A contraceptive kit of claim 15, wherein the first phase comprises 70 initial daily dosage units and the second phase comprises 14 daily dosage units.

23. (Original) A contraceptive kit of claim 15, wherein the first phase comprises 63 initial daily dosage units and the second phase comprises 7 daily dosage units.

24. (Previously Amended) A contraceptive kit of claim 15, wherein the competitive progesterone antagonist is:

17α-ethinyl-17β-hydroxy-11β-(4-methoxyphenyl)estra-4,9-dien-3-one,

11β-(4-acetylphenyl)-17β-hydroxy-17α-(1-propenyl)estra-4,9-dien-3-one,

(Z)-11β-(4-acetylphenyl)-17β-hydroxy-17α-(3-hydroxy-1-propenyl)estra-4,9-dien-3-one,

E' cont.

11β-(4-dimethylaminophenyl)-17β-hydroxy-17α-(1-propinyl)estra-4,9-dien-3-one,

(Z)-9,11α-dihydro-17β-hydroxy-17α-(3-hydroxy-1-propenyl)-6'-(3-pyridinyl)-4'*H*-naphth[3',2',1': 10,9,11]estra-4,9(11)-dien-3-one,

(Z)-11β-[4-(dimethylamino)phenyl]-17β-hydroxy-17α-(3-hydroxy-1-propenyl)-estr-4-en-3-one,

4',5'-dihydro-11β-[4-(dimethylamino)phenyl]-6β-methylspiro[estra-4,9-dien-17β, 2'(3'*H*)-furan]-3-one,

4',5'-dihydro-11β-[4-(dimethylamino)phenyl]-7β-methylspiro[estra-4,9-dien-17β, 2'(3'*H*)-furan]-3-one, or

11β-(4-acetylphenyl)-19,24-dinor-17,23-epoxy-17α-chola-4,9,20-trien-3-one, or a mixture thereof.

25. (Previously Amended) A contraceptive kit of claim 15, wherein the gestagen is:

gestodene,

progesterone,

levonorgestrel,

cyproterone acetate,

chlormadinone acetate,

drospirenone (dihydrospirorenone),

norethisterone,
norethisterone acetate,
norgestimate,
desogestrel,
3-ketodesogestrel, or
dienogest,

or a mixture thereof.

E'cont.

26. (Original) A contraceptive kit of claim 15, wherein the daily dosage of the gestagen is:

0.02-0.6 mg of levonorgestrel,
0.02-2.0 mg of cyproterone acetate,
0.01-0.3 mg of gestodene, or
0.02-0.3 mg of desogestrel,

or a bioequivalent dosage of another gestagen.

27. (withdrawn) A contraceptive kit of claim 15, wherein the gestagen gestodene is in a dosage of 0.02 to 0.075 mg.

28. (withdrawn) A contraceptive kit of claim 15, wherein the competitive progesterone antagonist (Z)-11β-[4-(dimethylamino)phenyl]-17β-hydroxy-17α-(3-hydroxy-1-propenyl)estr-4-en-3-one is in a dosage of 0.01-5 mg.

29. (Currently Amended) A contraceptive kit comprising a predetermined ordered daily sequence of at least 28 individual daily dosage units ~~comprising~~ for administration to a patient, wherein the predetermined ordered daily sequence comprises

a first phase of at least 21 separate initial ~~daily~~ dosage units ~~comprising~~ to be administered daily to said patient according to said predetermined order, each individual dosage unit comprising a competitive progesterone antagonist in an effective amount to inhibit ovulation during the first ~~above-named~~ phase; ~~and~~ followed in the ordered sequence by

a second phase of 5 to 28 separate ~~daily~~ dosage units to be administered daily to said patient, wherein each dosage unit of the second phase ~~comprising~~ comprises a gestagen,

wherein the daily dosage units are to be taken daily by a user in the ordered sequence such that the daily units of progesterone antagonist are taken initially followed by separate administration of the daily dosage units of gestagen, and

El cont.

~~wherein~~ the respective dosage units are in periodically repeating subunits separated from one another spatially and/or by other markings, and

~~whereby~~ the dosage units that are present in the first phase comprise at least 21 daily dosage units in a kit, and the daily dosage units that are present in the second phase comprise at least 7 daily dosage units.

30. (Original) A contraceptive kit of claim 29, wherein the individual subunits can be separated from one another by perforations or other devices suitable for separation.

31. (Original) A contraceptive kit of claim 29, wherein the separate subunits each contain 7 dosage units.

32. (Original) A contraceptive kit of claim 29, wherein the separate subunits of the first phase each contain 7 dosage units.

33. (Withdrawn) A method for contraception in a female mammal, comprising administering, in an at least 28-day sequential administration regimen:

a first phase of at least 21 initial daily dosage units comprising a competitive progesterone antagonist in an amount effective to inhibit ovulation during the first above-named phase, and

a second phase of 7 to 28 daily dosage units, wherein each dosage unit comprises a gestagen.

34. (Withdrawn) A method for contraception of claim 33, wherein during the first phase, 21 to 27 initial daily dosage units are administered.

35. (Withdrawn) A method for contraception of claim 33, wherein during the first phase, at least 28 and at most 77 initial daily dosage units are administered.

36. (Withdrawn) A method for contraception of claim 33, wherein during the first phase, 28 initial daily dosage units are administered.

E/cont. 37. (Withdrawn) A method for contraception of claim 33, wherein during the second phase, 7 to 14 daily dosage units are administered.

38. (Withdrawn) A method for contraception of claim 33, wherein the first phase comprises 21 initial daily dosage units and the second phase comprises 7 daily dosage units.

39. (Withdrawn) A method for contraception of claim 33, wherein the first phase comprises 23 or 24 initial daily dosage units and the second phase comprises 8, 7 or 6 daily dosage units, whereby the total number of daily dosage units of the first and the second phases is 30 or 31.

40. (Withdrawn) A method for contraception of claim 33, wherein the first phase comprises 70 initial daily dosage units and the second phase comprises 14 daily dosage units.

41. (Withdrawn) A method for contraception of claim 33, wherein the first phase comprises 63 initial daily dosage units and the second phase comprises 7 daily dosage units.

42. (Withdrawn) A method for contraception of claim 33, wherein the competitive progesterone antagonist is selected from:

17α-ethinyl-17β-hydroxy-11β-(4-methoxyphenyl)estra-4,9-dien-3-one,

11β-(4-acetylphenyl)-17β-hydroxy-17α-(1-propinyl)estra-4,9-dien-3-one,

(Z)-11β-(4-acetylphenyl)-17β-hydroxy-17α-(3-hydroxy-1-propenyl)estra-4, 9 dien-3-one,

11β-(4-dimethylaminophenyl)-17β-hydroxy-17α-(1-propinyl)estra-4,9-dien-3 one,

(Z)-9,11α-dihydro-17β-hydroxy-17α-(3-hydroxy-1-propenyl)-6'-(3-pyridinyl)4'H-naphth[3',2',1':10,9,11]estra-4,9(11)-dien-3-one,

(Z)-11β-[4-(dimethylamino)phenyl]-17β-hydroxy-17α-(3-hydroxy-l-propenyl)estr-4-en-3-one,

4',5'-dihydro- 11β-[4-(dimethylamino)phenyl]-6β-methylspiro [estra-4, 9-dien17β,2'(3'H)-furan]-3-one,

E'cont.

4',5'-dihydro-11β-[4-(dimethylamino)phenyl]-7β-methylspiro[estra-4,9-dien17β,2'(3'H)-furan]-3-one, or

11β-(4-acetylphenyl)-19,24-dinor-17,23-epoxy-l7α-chola-4,9,20-trien-3-one, or a mixture thereof.

43. (Withdrawn) A method for contraception of claim 33, wherein the gestagen is selected from:

gestodene,
progesterone,
levonorgestrel,
cyproterone acetate,
chlormadinone acetate,
drospirenone (dihydrospirorenone),
norethisterone,
norethisterone acetate,
norgestimate,
desogestrel,
3-ketodesogestrel, or
dienogest,

or a mixture thereof.

44. (Withdrawn) A method for contraception of claim 33, wherein the daily dosage of gestagen is

0.02-0.6 mg of levonorgestrel,
0.02-2.0 mg of cyproterone acetate,
0.01-0.3 mg of gestodene,

0.02-0.3 mg of desogestrel
or a bioequivalent dosage of another gestagen.

E' cont.

45. (Withdrawn) A method for contraception of claim 33, wherein the gestagen gestodene is in a dosage of 0.02 to 0.075 mg.

46. (Withdrawn) A method for contraception of claim 33, wherein the competitive progesterone antagonist (Z)-11(3-[4-(dimethylamino)phenyl]-1713-hydroxy-17a-(3hydroxy-1-propenyl)estr-4-en-3-one is in a dosage of 0.01-5 mg.

47. (cancelled)

48. (Original) A contraceptive kit of claim 30, wherein the separate subunits of the first phase each contain 7 dosage units.

49-50. (cancelled)

51. (Previously Added) The contraceptive kit of claim 31, wherein the separate subunits of the first phase each contain 7 dosage units.

52. (Previously Added) The multi-phase combination preparation of claim 1, wherein said progesterone antagonist induces amenorrhea.

53. (Currently Amended) A multi-phase combination preparation comprising a predetermined ordered daily sequence of at least 28 individual daily dosage units, ~~comprising~~ for administration to a patient, wherein the predetermined ordered daily sequence comprises

a first phase of at least 21 initial ~~daily~~ dosage units to be administered daily to said patient according to said predetermined order, each individual dosage unit comprising a competitive progesterone antagonist, ~~wherein said progesterone antagonist is administered~~ in an amount effective to inhibit ovulation and induce amenorrhea during the first phase, ~~and~~ followed in the ordered sequence by

E' cont.

a second phase of 5 to 28 separate ~~daily~~ dosage units to be administered daily to said patient, wherein each dosage unit of ~~this~~ the second phase ~~comprising~~ comprises a gestagen,

wherein the daily dosage units are to be taken daily by a user in the ordered sequence such that the daily units of progesterone antagonist are taken initially followed by separate administration of the daily dosage units of gestagen.